Parkinson's Disease and Parkinsonism
34
11
13
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.9%
1 terminated out of 34 trials
92.3%
+5.8% vs benchmark
3%
1 trials in Phase 3/4
25%
3 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (34)
Aim 3 Particle Swarm Optimization PIGD
Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients
Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
Context- and Terrain-aware Gait Analysis
Digitally-enhanced, Decentralized, Multi-omics Observational Cohort
Community Outreach for Palliative Engagement -- Parkinson Disease
Sleep-specific DBS Therapy in Parkinson's Disease
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
Voice-activated Intelligent Personal Assistant (VIPA) Intervention for People With Parkinson's Disease
Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD
STEM-PD Open Label Extension (OLE)
Mechanism and Application of DBS in the Treatment of PD
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit
STEM-Parkinson's Disease
Seated Tai Chi Improves Dynamic Finger Pointing Task and Sitting Balance Control in Subjects With Parkinson's Disease
Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD
Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson's Disease
Trial of Parkinson's And Zoledronic Acid